🫀 #Aficamten aprobado en China
Un nuevo tratamiento para pacientes adultos con
👉 HCM obstructiva
👉 NYHA II–III
📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#MYQORZO #MiocardiopatíaHipertrófica #HCM #Cardiología #EnfermedadesCardíacas #NYHA #ClaseFuncional #DengYueMedicinasEnHongKong

From #ESCCongress 2025 - Dr. Pablo Garcia-Pavia comments on the MAPLE-HCM study pitting #aficamten against #metoprolol for the treatment of symptomatic obstructive hypertrophic #cardiomyopathy.

Watch the full interview here 👉 buff.ly/D7X1xly

#CardioSky

Novel Oral Agent Proves Mettle in Obstructive Hypertrophic Cardiomyopathy Randomized trial pits cardiac myosin inhibitor against beta-blocker

The novel oral cardiac myosin inhibitor #aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy better than standard beta-blocker treatment, the MAPLE-HCM randomized trial showed. @chriskramermd.bsky.social
www.medpagetoday.com/meetingcover...

LBCT insights from SEQUOIA-HCM at #HeartFailure2025: #aficamten as effective in mildly symptomatic pts w/ #oHCM (NYHA class II/KCCQ-CSS ≥80) as in pts w/ moderate to severe sx. Now published in EHJ! doi.org/10.1093/eurheartj/ehaf364 #CardioSky #MedSky

Is #Aficamten Plus #Disopyramide More Effective Than Aficamten Alone in obstructive HCM?

#CardioSky #JACCHF
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @jimjanuzzi.bsky.social @robmentz.bsky.social @hvanspall.bsky.social @vietheartpa.bsky.social @load-dependent.bsky.social

The MAPLE-HCM study evaluates #aficamten vs #metoprolol to potentially redefine first-line therapy standards in hypertrophic obstructive cardiomyopathy. Details of the study design in #JACCHF: www.jacc.org/doi/10.1016/...

#oHCM #HCMAwarenessDay

📌 Impact of #Aficamten on Disease & Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From #SEQUOIAHCM

https://buff.ly/3Oz3PuN
#OHCM #HCM